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Smoking conventional cigarettes (CCs) exposes smokers to harmful and potentially harmful constituents
(HPHCs). The Tobacco Heating System 2.2 (THS 2.2), a candidate modiﬁed risk tobacco product, was
developed to reduce or eliminate the formation of HPHCs, while preserving as much as possible the taste,
sensory experience, nicotine delivery proﬁle and ritual characteristics of CC. This randomized, controlled,
open-label study in conﬁnement for 5 day exposure aimed to demonstrate the reduction in exposure to
selected HPHCs, to assess nicotine uptake and subjective effects, in participants switching to THS 2.2
(n ¼ 80) compared to participants continuing smoking CCs (n ¼ 40) and abstaining from smoking
(n ¼ 40). The subjects were randomized according to sex and daily CC consumption. The levels of bio-
markers of exposure to HPHCs were signiﬁcantly reduced in participants switching to THS 2.2, compared
to CC use. More importantly, the magnitude of exposure reduction observed was close to that which was
seen in participants who abstained from smoking for 5 days, while nicotine uptake was maintained.
Reduction in urge-to-smoke was comparable between THS and CC groups, however THS 2.2 was slightly
less satisfactory than CCs. The new, alternative tobacco product THS 2.2 was well tolerated.
© 2016 Philip Morris Products S.A. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Conventional cigarettes (CCs) cause serious diseases and the
best way to reduce the adverse health consequences of smoking is
to quit tobacco use. Although smoking prevalence has declined in
many countries over the last decades, millions of adults continue to
smoke CCs. Based on the World Health Organization's own pre-
dictions, there will be more than one billion smokers by the year
2025. Furthermore, success rates of currently available approaches
to quit CC smoking are low. Recognizing this, the policy of tobacco
harm reduction e making less harmful products available to
smokers who would otherwise continue smoking e has been put
forward and is supported by a multitude of stakeholders, including
public health organizations, healthcare professionals and, Research & Development, 5
iza).
ed by Elsevier Inc. This is an openregulators, to complement existing smoking prevention and
cessation strategies. The Tobacco Advisory Group of the Royal
College of Physicians opined in 2016 that “ if nicotine could be
delivered effectively and acceptably to smokers without smoke,
most if not all of the harm of smoking could probably be avoided”
(Royal College of Physicians, 2016).
In line with the current tobacco harm reduction strategy, Philip
Morris International (PMI) is developing reduced risk products
which replicate the sensorial, ritual and taste attributes of CCs as
much as possible, while delivering a respirable aerosol that pro-
vides users with a comparable nicotine delivery to CCs but that is
signiﬁcantly less harmful than CC smoke and, therefore, potentially
reduces the risk of smoking related diseases.
One of these products is THS 2.2, a heat-not-burn product which
marks an important milestone in the evolution of heat-not-burn
technology. The clinical study reported in this paper is part of a
global clinical program to assess exposure and disease risk reduc-
tion associated with the use of THS, one of PMI's reduced riskaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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product by the U.S. Food and Drug Administration (FDA) (FDA (Food
and Drug Administration) (2012a)). The study aimed to demon-
strate exposure reduction to a selected set of HPHCs when
switching from CCs to THS 2.2, as compared to continued CC use
and smoking abstinence (SA) for 5 days.
2. Material and methods
2.1. Participants
Adult healthy Japanese smokers, 23e65 years old, were eligible
if they smoked 10 commercially available non-menthol CCs per
day with a maximum yield of 1 mg nicotine per CC (ISO yield) for
the last 4 weeks and had smoked CC for 3 consecutive years prior
to enrollment. Study participants were recruited via the clinical
site's database and through advertisements. Before participation in
the study, all participants provided written informed consent and
underwent screening procedures, such as physical examination and
medical check-up. Only candidates not willing to quit smoking in
the forthcoming 3 months, but ready to accept a 5-day smoking
interruption could enroll in the study. Participants with clinically
relevant medical conditions, or who potentially required medical
interventions (start of treatment, surgery, or hospitalization), par-
ticipants with a history of alcohol and/or drug abuse, or who used
nicotineecontaining products other than their own brand of CCs, as
well as pregnant or breast feeding female subjects and female
unwilling to use acceptable methods of effective contraception,
were not allowed to participate. All participants were informed that
theywere free towithdraw from the study at any time; participants
willing to quit smoking after enrolment were encouraged to do so
and referred to a smoking cessation counselor to receive appro-
priate smoking cessation support. Participants were compensated
for their participation in the study.
2.2. Study design
This study was a controlled, randomized, 3 arm parallel, single-
center study in conﬁnement. The Screening Period covered a
maximum of 4 weeks (Day -30 to Day -3) prior to admission and
enrollment to the study site on Day -2. All subjects tested THS 2.2
using up to 3 THS Tobacco Sticks prior to enrollment. In female
participants, the THS 2.2 product test was performed only after a
negative urine pregnancy test. After all inclusion/exclusion criteria
had been met, eligible candidates were enrolled and conﬁned un-
der medical supervision until Discharge on Day 6. On Day -1 and
Day 0 (Baseline), participants smoked their own preferred brand of
CCs and baseline assessments were performed. On Day 0, 160
participants were randomized with stratiﬁcation by sex and
average self-reported daily CC consumption over 4 weeks prior to
enrollment (10e19 CC vs. >19 CC per day) in a 2:1:1 randomization
ratio to THS 2.2 use (n¼ 80), CC smoking (n¼ 40) or to abstain from
smoking (n ¼ 40). From Day 1 to Day 5, participants in the THS 2.2
and CC groups used THS 2.2 or their own brand of non-menthol
CCs, respectively, and exclusively. Participants in the SA arm were
asked to abstain from smoking. The use of nicotine replacement
therapy was not allowed. After Discharge on Day 6, or in case of an
early discontinuation, participants entered a 7-day Safety Follow-
Up Period for recording of spontaneously reported new adverse
events (AEs) or serious adverse events (SAEs), and follow-up of any
ongoing AEs/SAEs occurred during conﬁnement (Fig. 1). During the
designated smoking hours from 06:30 to 23:00, CC smoking was
allowed ad libitum on Day -1 and Day 0, and depending on the
participant's product allocation, exclusive use of THS 2.2 or exclu-
sive CC smoking was allowed ad libitum from Day 1 to Day 5.Twenty-four-hour urine was collected on each day.
The study protocol was approved by the local ethics committee
in July 2013, prior to study start and conducted at the Higashi
Shinjuku Clinic, located in central Tokyo, Japan, in accordance with
the declaration of Helsinki (World Medical Association (WMA),
2008), Good Clinical Practice guidelines as transposed into the
Japanese regulations (Ministry of Health and Welfare, 2013) and
national regulations. The study was registered on ClinicalTrials.gov
with ID: NCT01970982.
2.3. Study investigational products
The test product THS 2.2 was developed and provided by Philip
Morris Products S.A. (part of Philip Morris International group of
companies). THS 2.2 has three components: the THS tobacco Stick,
the holder, and the charger. The THS tobacco stick contains a to-
bacco plug of processed tobacco cast leaf, which is covered by a
paper wrap. The overall appearance of the THS tobacco stick is
similar to that of a CC, except it is much shorter. The holder includes
a battery, controlling electronics, and the heater element. The THS
tobacco stick is inserted into the holder, and an electronically
controlled heating blade within the holder heats the tobacco ac-
cording to a carefully controlled temperature proﬁle <350 C. The
charger recharges the holder. To use THS 2.2, the THS tobacco stick
is inserted into the holder, the heating of the THS tobacco stick is
initiated by pressing the button on the holder and a LED indicates
when the initial heating process is complete. The holder and THS
tobacco stick are designed to deliver over approximately 6 min or
around 14 puffs. At the end of each product use session, the THS
holder requires recharging and for the next use a new THS tobacco
stick must be used. The test product THS 2.2 contained 0.5 mg
nicotine and 4.9 ± 0.5 mg/stick of glycerin as determined under ISO
conditions using machine pufﬁng methods. The reference product
in this study were the participant's own preferred brand of non-
menthol CCs used in the CC group. CCs were not provided by the
Sponsor, and subjects were asked to buy and bring their own CCs to
the investigational site.
The disposition of THS 2.2 (tobacco sticks, charger and holders)
was managed by the site as per Investigational Product handling
manual. Subjects received one charger and two holders. Sticks were
distributed one by one for each product use on request of the
subject and used sticks were returned to the site staff. Distributed
and returned sticks were recorded in an accountability log.
The holders were cleaned following the instructions provided in
the THS 2.2 User Guide which included a brief cleaning after each
product use experience and a full cleaning using the heat-
generated self-clean procedure of THS 2.2 followed by a manual
cleaning process using the special cleaning kit provided after each
20 sticks.
2.4. Sample size estimation
The sample size was determined based on the expected least
squares (LS) mean ratios (THS/CC) of the concentrations of bio-
markers of exposure adjusted for creatinine (except for COHb), as
observed in previous studies with heated tobacco products
(ClinicalTrials.gov ID: NCT00812279; ID: NCT01780714). A total of
160 participants randomized at a ratio of 2:1:1 to the THS, CC and
SA groups respectively, were considered sufﬁcient to attain >80%
power to show a reduction of 50% in the concentrations of car-
boxyhemoglobin (COHb), 3-hydroxypropylmercapturic acid (3-
HPMA), monohydroxybutenyl mercapturic acid (MHBMA), and S-
phenylmercapturic acid (S-PMA) in the THS group relative to the CC
group, with a one-sided probability of 2.5% for type I error. The
overall type I error was preserved by simultaneously testing the
Fig. 1. Study Design. Study design schematic representation of the procedures followed by participants. Abbreviations: CC ¼ conventional cigarette use group; THS 2.2 ¼ Tobacco
Heating System 2.2 use group.
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The biomarkers of exposure were analyzed in all randomized
participants who used the allocated product at least once after
randomization and with at least one valid value for a biomarker of
exposure. Statistics were derived for each biomarker of exposure
and the change from baseline according to study group and study
day. Descriptive summary statistics included the number of par-
ticipants (n), number and percent of participants with missing data,
arithmetic mean, arithmetic standard deviation (SD), median, ﬁrst
and third quartiles, minimum, maximum, geometric mean and
associated 95% conﬁdence intervals (CI) and geometric coefﬁcient
of variation (CV) for each study group stratiﬁed by sex and CC use
for 4 weeks before enrollment.
Inferential analysis was performed on the endpoints related to
the primary objective including S-PMA, MHBMA, COHb, and 3-
HPMA as observed on Day 5. Analysis of covariance was conduct-
ed on log-transformed variables to estimate the ratios between the
study groups (one sided type I error of 2.5%) with adjustment for
sex, CC use over the 4 weeks before enrollment, and the baseline
value of the biomarkers of exposure. The estimated differences
between the study groups and associated CIs were back-
transformed to provide relative effects (THS/CC). A similar statis-
tical approach was applied for the other endpoints. All statistical
analyses were performed using Statistical Analysis Software (SAS),
version 9.3 (SAS Inc., Cary, NC, USA).2.6. Biomarkers of exposure
Biomarkers of exposure to selected HPHCs, were measured
throughout the study from Day -1 to Day 5. The HPHCs assessed in
this study were selected based on the following criteria:
1) HPHCs recommended for mandated lowering in cigarette
smoke as deﬁned by the WHO (WHO Study Group et al., 2008)and the draft guidance of the U.S. Food and Drug Administra-
tion (FDA) Center for Tobacco Products (CTP) on “Reporting
Harmful and Potentially Harmful Constituents in Tobacco
Products and Tobacco Smoke” (FDA (Food and Drug
Administration), 2012b).
2) The HPHC is speciﬁc to cigarette smokewith other sources being
minor or non-existent.
3) The biomarker of exposure to a HPHC is easily detectable using
validated, reliable, reproducible, ﬁt-for-purpose analytical
methods.
4) The HPHC reﬂects a speciﬁc toxic exposure or be a reliable
surrogate of exposure to HPHCs.
5) The list of HPHCs includes HPHCs from both the gas and par-
ticulate phases.
6) The list of HPHCs includes a broad variety of chemical classes
and organ toxicity classes as deﬁned by the FDA (carcinogen,
cardiovascular toxicant, respiratory toxicant, reproductive and
development toxicant, addiction potential) (FDA (Food and Drug
Administration), 2012b).
7) The list of HPHCs includes HPHCs formed at different temper-
ature levels.
8) The HPHCs selected for measurement vary in their elimination
half-life times, ranging from a few hours up to more than 2
weeks.
The study included biomarkers of exposure to the tobacco-
speciﬁc HPHCs 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NNK), and N-nitrosonornicotine (NNN), as well as biomarkers of
exposure to 1,3-butadiene, acrolein, benzene, carbon monoxide,
pyrene, benzo(a)pyrene, 4-aminobiphenyl, 1-aminonaphthalene,
2-aminonaphthalene, o-toluidine, acrylonitrile, ethylene oxide,
toluene and crotonaldehyde. In total, 16 HPHCs were evaluated to
assess exposure reduction in the THS group compared to the CC and
SA groups (Table 1).
Biomarkers of exposure to nicotine (nicotine and cotinine in
plasma and nicotine equivalents measured in 24-h urine: free
nicotine, nicotine-glucuronide, free cotinine, cotinine-glucuronide,
free trans-3’-hydroxycotinine, trans-3’-hydroxycotinine-
Table 1
List of biomarkers of exposure and corresponding harmful and potentially harmful constituents.
Acronym Biomarker of exposure HPHC
Total NNALa Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
Total NNN Total N-nitrosonornicotine N-nitrosonornicotine (NNN)
MHBMA Monohydroxybutenyl mercapturic acid 1,3-butadiene
3-HPMA 3-hydroxypropylmercapturic acid Acrolein
S-PMA S-phenylmercapturic acid Benzene
COHb Carboxyhemoglobin1 Carbon monoxide
Total 1-OHPb Total 1-hydroxypyrene Pyrene





CEMA 2-cyanoethylmercapturic acid Acrylonitrile
HEMA 2-hydroxyethylmercapturic acid Ethylene oxide
3-HMPMA 3-hydroxy-1-methylpropylmercapturic acid Crotonaldehyde
S-BMA S-benzylmercapturic acid Toluene
Biomarkers of exposure matrix is 24 h urine if not otherwise stated. Other matrixes; 1¼ blood. HPHC¼ harmful or potentially harmful smoke constituent. a¼ Total NNAL was
determined as the molar sum of 4-(methylnitrosamino)-1-(3-pyridy1)-1-butanol and its O-glucuronide conjugate. b ¼ Total 1-OHP was determined as the molar sum of 1-
hydroxypyrene and its glucuronide and sulfate conjugates.
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nicotine when smokers use THS 2.2 or smoke CCs.
Biomarkers of exposure to selected HPHCs, were measured in
blood collected from Day 0 to Day 5, or 24-h urine samples
collected throughout the study from Day -1 to Day 5. Creatinine
was also measured in 24-h urine for adjustment of the concentra-
tion of all urinary biomarkers of exposure. With the exception of
the samples collected for carboxyhemoglobin (COHb), samples
were processed and stored at 20 C pending biomarker analysis.
Nicotine, cotinine, trans-30-hydroxycotinine, were measured in
plasma and following a solid phase extraction, the extracts were
injected onto a qualiﬁed LC-MS/MS instrument.
O-toluidine, 1-aminonaphthalene, 2-aminonaphthalene, 4-
aminobiphenyl, S-phenylmercapturic acid, total 1-hydroxypyrene,
total 3-hydroxy benzo[a]pyrene, total NNAL, and total NNN were
measured in urine after hydrolysis. In addition to the total assays,
nicotine equivalents were also measured with the direct analysis of
nicotine, cotinine, trans-30-hydroxycotinine, nicotine-N-
glucuronide, cotinine-N-glucuronide, and trans-30-hydrox-
ycotinine-O-glucuronide in urine. A direct analysis of urinary con-
centrations of MHBMA, 3-HPMA, HMPMA, CEMA, S-BMA, were
performed. All analysis were conducted with a qualiﬁed LC-MS/MS
instrument. All bioanalytical assays used were validated to meet
the requirements of the FDA Guidance to Industry: Bioanalytical
Method Validation (FDA (Food and Drug Administration), 2001).
Urinary creatinine was measured spectrophotometrically using
a College of American Pathology (CAP)/Clinical Laboratory
Improvement Amendments (CLIA) validated assay.
All laboratory analyses were carried out at Celerion Laboratories
(Lincoln NE, USA) except for COHb which was assessed by Tokiwa
Chemical Industries Co. (Tokyo, Japan). Details on the bioanalytical
methods conducted at Celerion Laboratories are reported in (Haziza
et al., under revision).2.7. Cytochrome 1 A2 activity
Because CYP1A2 is an enzyme inducible by polycyclic aromatic
amines, some HPHCs found in cigarette smoke (Butler et al., 1992),
CYP1A2 activity was measured in this study as an indicator of
overall exposure. Cytochrome P450 (CYP) 1A2 enzymatic activity
wasmeasured on Day 0 and on Day 5. It was based on the post-dose
paraxanthine (PX) and caffeine (CAF) plasma molar concentrations
approximately 6 h (±15 min) after the intake of one Tomerumin®(LionCorp.) caffeine tablet (around 170 mg caffeine) with
150 ml ± 10 ml water. CYP1A2 activity was assessed by measuring
PX and CAF concentrations and calculating the PX/CAF molar
metabolic ratio (Faber and Fuhr, 2004).2.8. Product use and human pufﬁng topography
CC and THS tobacco stick consumption was recorded for all
participants from Day -2 until discharge. All products were
dispensed and recorded one at a time by the site staff at the par-
ticipant's request. Smoking abstinence for participants in the SA
group was veriﬁed by CO breath tests performed 4 times/day
(CO < 10 ppm). Human pufﬁng topography (HPT) was performed to
measure parameters such as puff duration, inter-puff interval, puff
volume, and total volume for each CC used at baseline in all par-
ticipants, and on Days 1 and 4, in both the CC and THS groups. HPT
was performed using the HPT SODIM® device, model SPA/M
(SODIM® Instrumentation, Fleury les Aubrais, France).
The sample holders for the HPT Sodim® Device were speciﬁcally
designed for compatibility with THS 2.2 and the HPT Sodim®Device
and sample holder were validated according to PMI's internal
quality management system to ensure that measurements per-
formed with the device and sample holder are accurate and
repeatable. Furthermore pufﬁng topography was only assessed in
subjects who smoked CCs that were compatible with the HPT de-
vice. Users of slim CCs were excluded from HPT assessments.2.9. Subjective effects
The subjective effects were assessed using self-reported ques-
tionnaires validated for use in the local language. Nicotine depen-
dence was assessed at the Screening Visit using the revised version
of the Fagerstr€om Test for Nicotine Dependence (FTND)
(Fagerstrom et al., 2012). Product evaluation was performed using
the modiﬁed Cigarette Evaluation Questionnaire (mCEQ)
(Cappelleri et al., 2007) on Day1 in all participants, and fromDays
1e5 in the THS and CC groups. The following domains of the mCEQ
were evaluated: Smoking Satisfaction (satisfying, tastes good, and
enjoyment of smoking); Psychological Reward (calms down, makes
more alert, reduces irritability, helps concentration, reduces hun-
ger); Aversion (dizziness, nausea); Enjoyment of Respiratory Tract
Sensations (single-item assessment); and Craving Reduction (sin-
gle-item assessment). The urge-to-smoke, which evaluates how
Table 2
Demographic characteristics by group, at baseline.
Variable and statistic THS CC SA
Randomized, n 80 40 40
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to smoke, was assessed in all participants on a daily basis from
Day 1 to Day 5 using the 10-item brief version of the Question-
naire of Smoking Urges (QSU-brief) (Cox et al., 2001).Completed, n 80 40 38
Sex n (%)
Male 40 (50.0%) 20 (50.0%) 20 (50.0%)
Female 40 (50.0%) 20 (50.0%) 20 (50.0%)
Age (years)
Mean ± SD 37.6 ± 11.7 37.2 ± 11.7 35.9 ± 10.6
Range 23e64 23e65 23e64
BMI (kg/m2)
Mean ± SD 22.7 ± 2.7 22.9 ± 2.7 22.7 ± 2.8
Range 18.6e30.8 18.6e28.7 18.7e28.8
CC consumption n (%)
10 to 19 cig/day 44 (55.0%) 22 (55.0%) 21 (52.5%)
>19 cig/day 36 (45.0%) 18 (45.0%) 19 (47.5%)
FTND total score
Mean ± SD 4.6 ± 1.7 4.0 ± 1.7 4.3 ± 1.7
Range 1e8 1e8 1e9
Abbreviations: CC ¼ conventional cigarette use group; SA ¼ smoking abstinence
group; THS ¼ Tobacco Heating System 2.2 use group; SD ¼ standard deviation;2.10. Adverse events, medical history, concomitant medication,
product malfunction and misuse
Safety assessment included AEs, SAEs, THS 2.2 malfunctions and
misuse, vital signs, electrocardiography, spirometry, clinical
chemistry, hematology, urinalysis, physical examinations and use
of concomitant medications. AEs were recorded from the time of
signing the informed consent form until the end of the study (end
of the Safety Follow-Up Period). AEs, concomitant diseases, and
medical/surgical history were coded using the Medical Dictionary
for Regulatory Activities (MedDRA version 16.0). Prior and
concomitant medications were coded according to the World
Health Organization enhanced drug dictionary (Uppsala
Monitoring Centre, Q1 2013).BMI ¼ body mass index; FTND ¼ Fagerstr€om Test for Nicotine Dependence,
ISO ¼ International Organization for Standardization.3. Results
3.1. Participants
The study site screened 267 subjects, 101 were screen failures,
and 166 tried THS 2.2 during the product test phase. The 166 par-
ticipants who tried THS 2.2were enrolled and included in the safety
population. Among these participants, 6 were not randomized;
either due to participants' personal reasons, or due to randomiza-
tion quota already being met. One hundred sixty participants were
randomized, with 80, 40, and 40 participants in the THS 2.2, CC, and
SA groups, respectively. One hundred ﬁfty eight participants
completed the study with 2 participants in the SA group who
voluntarily withdrew from the study (Fig. 2).
No difference in terms of age, body mass index, and mean FTND
total scores was observed between the study groups at Baseline.
Overall, the majority of enrolled participants (55.4%) had a mod-
erate FTND score. The distribution of participants between the 3
groups regarding sex and daily cigarette consumption was com-

























Fig. 2. Disposition of Cases. Description of participants' disposition in the course of the st
group; THS 2.2 ¼ Tobacco Heating System 2.2 use group.3.2. Number of THS Tobacco Sticks and CCs used daily
In the THS group, the mean number of THS tobacco sticks
(mean ± SD) used daily initially decreased from the number of CCs
smoked at Baseline (10.3 ± 3.4) to Day 1 (8.3 ± 3.0), increasing
afterwards with product use comparable to Baseline on Day 5
(9.9 ± 3.9). The mean number of CCs consumed in the CC group
daily was 10.5 ± 3.0 at Baseline and increased from 10.6 ± 3.1 on
Day 1e12.5 ± 3.5 on Day 5. Over the study period, participants in
the THS 2.2 group consumed on average about 2 THS tobacco sticks
less compared to the number of CCs smoked in the CC group on a
day by day basis (Table 3).3.3. Biomarkers of exposure to selected HPHCs
Levels of biomarkers of exposure to 16 HPHCs and to nicotine
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Screening criteria not met = 47
Declined = 12
Other = 42
udy. Abbreviations: CC ¼ conventional cigarette use group; SA ¼ smoking abstinence
Table 3






Mean ± SD 10.3 ± 3.43 10.5 ± 2.97
Range 2e19 4e19
Day 1
Mean ± SD 8.3 ± 3.03 10.6 ± 3.02
Range 1e15 3e19
Day 2
Mean ± SD 9.5 ± 3.61 11.9 ± 3.38
Range 1e18 6e19
Day 3
Mean ± SD 9.9 ± 3.87 12.0 ± 3.25
Range 1e20 5e18
Day 4
Mean ± SD 9.9 ± 3.84 11.8 ± 2.90
Range 1e19 6e17
Day 5
Mean ± SD 9.9 ± 3.93 12.5 ± 3.52
Range 1e19 6e20
Abbreviations: CC ¼ conventional cigarette use group; SA ¼ smoking abstinence
group; THS ¼ Tobacco Heating System 2.2 use group; SD ¼ standard deviation.
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of exposure were comparable in all three groups. On Day 5, at the
end of the exposure period, the levels of 15 biomarkers of exposure
(COHb, S-PMA, MHBMA, 3-HPMA, total NNN, total NNAL, total 1-
OHP, 4-ABP, 1-NA, 2-NA, o-toluidine, CEMA; HEMA, 3-HMPMA,
and total 3-OH-B[a]P) were reduced in both THS and SA groups as
compared to Baseline (Fig. 3, Supplementary Table 2). The reduc-
tion was of similar magnitude between the THS and SA groups for
each biomarker except for total NNN, 3-HPMA, total NNAL, total 3-
OH-B[a]P and HMPMA for which the reduction was slightly higher
in SA than THS groups.
Substantial reductions in urinary concentrations adjusted for
creatinine, of approximately 76% (ratio 23.09%) in MHBMA, 47%
(ratio 52.86%) in 3-HPMA, 84% (ratio 15.68%) in S-PMA, and 52%
(ratio 47.10%) in COHb (in blood) were demonstrated after 5 days of
switching to THS use as compared to continuing smoking.
Furthermore reductions of 50% (ratio 49.03%) in total NNAL, 69%
(ratio 30.06%) in total NNN, 53% (ratio 46.44%) in total 1-OHP, 81%
(ratio 18.21%) in 4-ABP, 95% (ratio 4.44%) in 1-NA, 82% (ratio 17.62%)
in 2-NA, 49% (ratio 50.52%) in o-toluidine, 78% (ratio 21.21%) in
CEMA, 53% (ratio 46.50%) in HEMA, 62% (ratio 37.71%) in 3-HMPMA
and 70% (ratio 29.99%) in total 3-OH-B[a]P were observed in the
THS group relative to the CC group (Table 4).
Despite the fact that S-BMA is suitable to detect toluene in
environmental and occupational studies (Lovreglio et al., 2010), in
this study it could not discriminate between smokers and smokers
who stop smoking, an observation reported by other authors as
well (Supplementary Tables 1 and 2) (Imbriani et al., 1999;
Schettgen et al., 2008).
No change in the levels of creatinine was observed at baseline
and after 5 days of exposure (Supplementary Table 3).
3.4. Exposure to nicotine
Nicotine exposure as assessed by NEQ was lower at Day 1 in the
THS group compared to the CC group (4.55 vs. 5.32 mg/g creat)
before increasing afterwards and reaching similar levels of NEQ
between THS 2.2 users and participants who continued to smoke
CC (THS 2.2 vs. CC ratio 97.72%) at Day 5. In both groups, NEQ values
increased from baseline to Day 5 with percent changes from
baseline of 16.94% and 9.49% for the THS and CC groups, respec-
tively. In agreement with the results for NEQ, plasma nicotine andconcentration proﬁles were comparable for the THS and CC groups,
with similar mean nicotine concentrations reported on all days
except on Day 1 when the nicotine plasma concentration in the THS
group (10.46 ng/mL) was lower than that of the CC group (14.68 ng/
mL). Nicotine concentrations increased fromDay 1 to Day 5 for both
the THS and CC groups with a remaining negligible difference be-
tween the groups of about 6.01% on Day 5.
Plasma cotinine concentration proﬁles were comparable for the
THS and CC groups, with similar concentrations reported at base-
line (140.37 and 147.32 ng/mL, respectively) and Day 5 (161.00 and
164.30 ng/mL, respectively). Mean plasma cotinine concentrations
increased by approximately 16.14% and 6.63% from Baseline to Day
5 in the THS and CC groups respectively.
3.5. Cytochrome 1A2 activity
At baseline, CYP1A2 activity was similar in all three groups. On
Day 5, the CYP1A2 activity following coffee intake was 56.56% and
76.50% in the THS and CC groups, respectively, with difference THS-
CC of 21.65% (95% CI: 25.49, 17.81). In the THS group, CYP1A2
activity reduced from baseline to Day 5 by 27.36% (95%
CI: 30.51, 24.22) to levels comparable to the SA group (LS mean
difference THS-SA: 2.29% (95% CI: 1.62, 6.19)).
3.6. Human pufﬁng topography
The baseline values for each assessed HPT parameter were
similar in the THS and CC groupswhile subjects were smoking their
own preferred brand of CC and were generally stable in the CC
group between baseline and Day 4 with the exception of total
number of puffs and total puff volume which decreased slightly in
CC arm on Day 1 and average inter puff interval which increased
from baseline to Day 4.
In the THS group, total puff volume and average puff volume
were 18% and 25% lower on Day 1 relative to the CC group. From
Day 1 to Day 4 both parameters increased with similar values for
total puff volume and a remaining difference of 15% for average puff
volume between the CC and THS group.
In contrast, on Day 1, the total number of puffs and the puff
frequency were 11% and 18% higher in the THS group relative to the
CC group respectively. In addition the total puff duration was 11%
longer in the THS group compared to the CC group on Day 1. These
differences further increased on Day 4 with the total number of
puffs and the puff frequency being about 19% and 27% higher and
the total puff duration 23% longer in the THS relative to CC group.
No notable differences were observed in average puff duration
and total smoking duration on both Days 1 and 4 between partic-
ipants who switched to THS 2.2 use and participants who
continued to smoke CC (Table 5).
3.7. Modiﬁed cigarette evaluation questionnaire subscales
The mCEQ results showed that on Day 5, compared to baseline,
smoking satisfaction was lower for participants who switched to
THS 2.2 use compared to participants who continued to smoke CC,
with differences of 0.69. Aversion, craving reduction, and enjoy-
ment of respiratory tract sensation, and psychological reward were
comparable in the THS and CC groups on Day 5 (Table 6).
Descriptive statistics for each sub-item of the mCEQ (mean scores)
are provided on Day 5 in Fig. 4 for the THS and CC groups.
3.8. Urge-to-smoke symptoms (QSU-Brief)
The mean urge-to-smoke total scores were comparable in all
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Fig. 3. Biomarkers of exposure relative (%) change from baseline to end of exposure (Day 5) per study group. Relative change from baseline. Results presented are the
geometric means (95% conﬁdence interval) values for each biomarker of exposure. Abbreviations: SA ¼ smoking abstinence group; THS ¼ Tobacco Heating System 2.2 use group.
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comparable between the THS and CC groups throughout the study,
with the minimum and maximum values ranging from 1.0 to 6.7 in
the THS group, and from 1.0 to 5.8 in the CC group (Fig. 5).
Considering all of the time-points, the LS mean difference in the
QSU-brief total score between the THS and CC groups was 0.13 (95%
CI: 0.19, 0.45).
In the SA group, as expected, the urge-to-smoke total score
increased signiﬁcantly from 3.98 at baseline to 4.64 on Day 1, cor-
responding to an increase of 0.66 (95% CI: 4.20, 5.08). From Day 3
onwards, the urge-to-smoke started to decrease but remained
above the baseline value on Day 5 (Fig. 5). The LSmean difference in
QSU-brief total score between the THS group and the SA group
was 0.65 (95% CI: 0.98, 0.32).3.9. Safety
The safety population consisted of 166 participants comprised
out of the 160 randomized participants and the 6 participants who
were exposed to THS from the product test on Day -2, but not
randomized. Overall, there were 11 AEs reported by 10 of the 166participants (6.0%) in the safety population, all of which were mild
in intensity. The incidence and frequency of AEs were comparable
in the THS (6 AEs in 6/80 participants [7.5%]), the CC (4 AEs in 3/40
participants [7.5%]), and the SA groups (1 AE in 1/40 participants
[2.5%]). The most frequent AEs reported in the THS 2.2 or CC group
were blood triglycerides increased, neutrophil count decreased,
blood potassium decreased, protein urine present, and white blood
cell count decreased. The only AE reported after SAwas hemoglobin
decreased (Table 7).
There were no SAEs and none of the randomized subjects were
discontinued from the study because of an AE. None of the AEs
reported were assessed as being related to THS 2.2 or CC use.4. Discussion
The study demonstrated reductions in biomarkers of exposure
to selected HPHCs by switching from CC smoking to THS 2.2 use.
The conﬁnement setting allowed the investigation of the exposure
reduction to HPHCs achievable under ideal, conﬁned conditions
and monitored product compliance after 5 days of THS 2.2 use
compared to CC smoking, using SA as a benchmark. To assess the
Table 4
Biomarkers of exposure, ratios of THS relative to CC (%).
Biomarkers of exposure Ratio THS/CC (% and CI)
NEQ (mg/g creat) 104.89 (92.03; 119.55)
Nicotinea (ng/mL) 112.91 (91.36; 139.54)
Cotininea (ng/mL) 96.14 (70.73; 130.67)
Total NNAL (pg/mg creat) 49.03 (41.95; 57.30)
Total NNN (pg/mg creat) 30.06 (23.74; 38.06)
COHbb (%) 47.10 (44.30; 50.08)
MHBMA (pg/mg creat) 23.09 (18.41; 28.95)
3-HPMA (ng/mg creat) 52.86 (45.67; 61.17)
S-PMA (pg/mg creat) 15.68 (13.09; 18.78)
Total 1-OHP (pg/mg creat) 46.44 (41.32; 52.19)
4-ABP (pg/mg creat) 18.21 (15.29; 21.69)
1-NA (pg/mg creat) 4.44 (3.80; 5.18)
2-NA (pg/mg creat) 17.62 (14.72; 21.08)
o-tol (pg/mg creat) 50.52 (42.28; 60.38)
CEMA (ng/mg creat) 21.21 (18.10; 24.86)
HEMA (pg/mg creat) 46.50 (39.53; 54.69)
3- HMPMA (ng/mg creat) 37.71 (31.57; 45.05)
Total 3-OH- B[a]P (fg/mg creat) 29.99 (24.84; 36.20)
Geometric least squares mean ratio (%) (95% conﬁdence intervals) from an ANCOVA
model conducted on log-transformed Day 5 values with log-transformed baseline
value, study arm, sex and CC consumption reported at screening as ﬁxed effect
factors (THS/CC) on Day 5. a) Weighted average concentration over 24 h (Cavg); for
nicotine and cotinine the ratio is calculated on the weighted average concentration
over 24 h, b) Measured between 8:00 p.m. and 10:00 p.m. Abbreviations:
CC ¼ conventional cigarette group; THS ¼ Tobacco Heating System 2.2 group.
Table 5
Human pufﬁng topography parameters.





Total puff volume (mL)
Baseline 738.71 ± 321.26 801.53 ± 294.08
Day 1 623.68 ± 318.70 753.60 ± 282.90 81.58 (68.90; 96.58)
Day 4 705.25 ± 330.46 742.09 ± 299.67 99.24 (85.90; 114.64)
Average puff volume (mL)
Baseline 49.86 ± 18.84 51.02 ± 16.13
Day 1 39.42 ± 19.47 50.84 ± 15.49 74.78 (66.42; 84.20)
Day 4 42.20 ± 19.30 49.22 ± 16.14 85.45 (75.93; 96.16)
Average puff duration (s)
Baseline 2.01 ± 0.80 1.76 ± 0.56
Day 1 2.07 ± 0.93 1.82 ± 0.54 99.14 (91.36; 107.60)
Day 4 2.10 ± 1.00 1.80 ± 0.60 102.64 (93.42; 112.78)
Total puff duration (s)
Baseline 30.54 ± 14.68 27.31 ± 8.21
Day 1 33.62 ± 18.43 26.86 ± 8.32 110.91 (96.69; 127.22)
Day 4 36.68 ± 19.58 27.07 ± 8.83 123.45 (108.14; 140.93)
Total number of puffs
Baseline 15.47 ± 5.30 16.15 ± 4.84
Day 1 16.44 ± 5.63 15.13 ± 4.62 111.04 (100.84; 122.27)
Day 4 17.68 ± 5.63 15.50 ± 4.61 118.57 (109.35; 128.57)
Puff frequency (puffs/min)
Baseline 3.79 ± 1.09 4.10 ± 1.16
Day 1 4.26 ± 1.47 3.84 ± 1.19 117.76 (107.74; 128.72)
Day 4 4.55 ± 1.73 3.77 ± 1.11 126.61 (114.73; 139.72)
Comparative assessment of human pufﬁng topography parameters. Parameters are per THS tobacco stick/cigarette. All values are mean and standard deviation,
except THS/CC mean ratio; adjusted geometric least squares means ratio (%), and 95% conﬁdence intervals. Abbreviations: CC ¼ conventional cigarette use group;
THS ¼ Tobacco Heating System 2.2 use group.
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study included endpoints to investigate the adaptation to and
acceptance of THS 2.2 through the assessment of HPT and subjec-
tive effects.
The study demonstrated that switching to THS 2.2 leads to
reduction in COHb, S-PMA, MHBMA, and 3-HPMA, 4 biomarkers of
exposure to the following HPHCs: carbon monoxide, benzene, 1e3
butadiene, and acrolein respectively, after 5 days of use in a
controlled setting relative to smoking CC. Furthermore, reductions
in an additional 11 biomarkers of exposure were observed insubjects using THS 2.2 for 5 days compared to subjects continuing
to smoke CC. Biomarkers of exposure to HPHCs were compared
between THS 2.2, the participant's own brand of non-menthol CCs,
and smoking abstinence. Overall, the reduction in exposure to
HPHCs assessed in this study were comparable to those observed in
the smoking abstinence group. Themore pronounced differences in
total NNN levels in the THS arm compared to the SA arm compared
to those of total NNAL is likely related to the half-life of total NNAL
which is longer (10e18 days) (Goniewicz et al., 2009) than that of
total NNN. Considering that it is normally assumed that complete
elimination is achieved following 4 to 5 half-life, only initial and
progressive decrease for is observed for total NNAL when maximal
magnitude of reduction is probably achieved for total NNN after 5
days of THS exposure. Another possible explanation might be
related to a direct evaporative transfer of both compounds
(Rodgman and Perfetti, 2013) which could occur at higher rate for
NNK vs NNN when tobacco is heated to temperature below py-
rolysis (Forster et al., 2015).
Statistical analysis conducted on urinary biomarkers of expo-
sure expressed as quantity excreted, showed a comparable
magnitude of reduction to when biomarkers of exposure were
expressed as concentration adjusted to creatinine (data not re-
ported). These data along with the creatinine values which did not
show any variation of excretion between baseline and after 5 daysof exposure suggest that adjustment of the concentrations of uri-
nary biomarker of exposure to creatinine does not bring additional
variability.
Cigarette smoke contains thousands of chemicals, and over a
hundred are classiﬁed as HPHCs (Rodgman and Perfetti, 2013). In
2012, the US FDA published an abbreviated list of 20 HPHCs, from
which 18 constituents in cigarette smoke were recommended to
be measured and reported (FDA (Food and Drug Administration),
2012b). The present study assessed 16 HPHCs in addition to
nicotine, including 14 of the HPHCs requested by the FDA and 9
Table 6
Analysis of change from baseline in mCEQ.
Subscale THS CC (THSCC) difference
N ¼ 80 N ¼ 40
Smoking satisfaction 1.15 0.47 0.69 (1.04, 0.34)
Aversion 0.16 0.17 0.01 (0.19, 0.21)
Craving reduction 0.92 0.75 0.17 (0.59, 0.25)
Enjoyment of respiratory tract sensation 0.55 0.21 0.34 (0.74, 0.06)
Psychological reward 0.75 0.57 0.18 (0.42, 0.07)
Adjusted LS means and 95% CIs from an ANCOVA model with study arm, sex, CC consumption reported at Screening Visit, and study arm  day ﬁtted as ﬁxed effect
factors with baseline ﬁtted as a covariate. Day ﬁtted as a repeated factor. Abbreviations: CC ¼ conventional cigarette use group; THS ¼ Tobacco Heating System 2.2 use
group. CI ¼ conﬁdence interval; mCEQ ¼ modiﬁed cigarette evaluation questionnaire.
Fig. 4. mCEQ Subscales mean score for each sub items on Day 5.Mean score for each
sub items of the mCEQ questionnaire at Day 5 in the THS and CC groups.; Abbrevia-
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Fig. 5. Questionnaire on smoking urges mean total score. Comparison of the urge-to-sm





Total AEs (%) 6 (7.5%)
Blood triglycerides increased 2 (2.5%)
Neutrophil count decreased 2 (2.5%)
Blood potassium decreased 1 (1.3%)
Hemoglobin decreased 0
Protein urine present 1 (1.3%)
White blood cell count decreased 0
Adverse events occurred during the study. Terms coded using MedDRA® version 16.0. A
subjects in the column headers. AE ¼ adverse event; CC ¼ conventional cigarette use gro
Overall Safety ¼ Participants exposed at least once to THS 2.2.
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lowered in cigarette smoke (FDA (Food and Drug Administration),
2012b; WHO Study Group et al., 2008). We also measured expo-
sure to pyrene (as total 1-OHP), an indicator of exposure to
polycyclic aromatic hydrocarbons (PAH), and exposure to the ar-
omatic amine o-toluidine (o-tol), as both, PAH and o-toluidine are
strong carcinogens, associated with colon and bladder cancer
(IARC (International Agency for Research on Cancer), 2012).
Ethylene oxide (HEMA) was assessed because inhalation of
ethylene oxide is irritating to mucous membranes including those
associated with the respiratory system (U.S. Department of Health
and Human Services et al., 1990). In summary, the group of bio-
markers of exposure assessed in this work covers HPHCs of mul-




oke total scores derived from the QSU-brief. Results are presented as the mean (95%







3 (7.5%) 1 (2.5%) 10 (6.0%)
2 (5.0%) 0 4 (2.4%)
1 (2.5%) 0 3 (1.8%)
0 0 1 (0.6%)
0 1 (2.5%) 1 (0.6%)
0 0 1 (0.6%)
1 (1.25%) 0 1 (0.6%)
bbreviations: N ¼ number of subjects Percentages were calculated using the N of
up; SA ¼ smoking abstinence group; THS ¼ Tobacco Heating System 2.2 use group;
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different formation temperatures and, therefore, should provide
relevant evidence that THS 2.2, as a heat-not-burn-product, re-
duces HPHC exposure.
Four HPHCs present on the FDA's list; ammonia, formalde-
hyde, acetaldehyde and isoprene, were not measured. Isoprene
was not considered because of the high amount of endogenous
production (OECD (Organization for Economic Co-operation and
Development), 2005), and because of the very short half-life.
Isoprene levels in humans have not been reported as being reli-
able to distinguish smokers and non-smokers (Euler et al., 1996).
Acetaldehyde was not measured because of the lack of an
established biomarker of exposure. Because of the various sour-
ces of exposure to formaldehyde including environment, its short
half-life and lack of a speciﬁc metabolite, exposure to formalde-
hyde was also not measured in this study. No known speciﬁc
biomarker of exposure to ammonia exists in humans or animals
and, no evidence for alterations in clinical indices of body
ammonia or nitrogen levels after exposure to exogenous
ammonia has been reported (U.S. Department of Health and
Human Services, 2004). Due to the rapid clearance of ammonia
from the body or its metabolization to compounds found
endogenously at appreciable levels, ammonia is not a suitable
biomarker of exposure in the context of the assessment of a
candidate MRTP such as THS 2.2.
The study showed that switching from CCs to THS 2.2 for 5 days
reduced biomarkers of exposure to HPHCs to values between 47%
and 96%, and approached exposure reduction observed in the SA
group. The fact that total NNN, 3-HPMA, total NNAL, 3-HMPMA and
total 3-OH-B[a]P were slightly higher in the THS group relative to
SA, can likely be explained by the remaining levels of these HPHCs
in the THS 2.2 aerosol as evaluated by the smoke chemistry
(Schaller et al., 2016). Also, the formation through heating of glyc-
erin might add other possible explanations (Qadariyah et al., 2011).
Overall, the observed results strongly support the approach of
heating versus burning tobacco to reduce the exposure to HPHCs in
smokers using THS 2.2 while allowing users to effectively keep
nicotine levels close to CC.
CYP1A2 catalyzes many of the reactions involved in the meta-
bolism of low therapeutic-index drugs and synthesis of cholesterol,
steroids, and other lipids (Kroon, 2007). More importantly, CYP1A2
enzymes are monooxygenase involved in the activation of carci-
nogenic heterocyclic and aromatic amines, strong carcinogens
associated with colon and bladder cancer (Gunes and Dahl, 2008;
MacLeod et al., 1997). The CYP1A2 expression itself is induced to
a large extent by polycyclic aromatic hydrocarbons (PAH) which are
found in cigarette smoke (Butler et al., 1992).
The 70% relative reduction of total 3-OH-B[a]P, after 5 days of
THS use compared to CC, likely contributes to the 27% reduction
from baseline in CYP1A2 activity in the THS group, similar to the
reduction in the SA group. This may further support the potential of
THS to lower the risk of certain tobacco-related cancers. Corrobo-
rating the data from human exposure, a previously reported study
conducted in Apoe/ mice for 8 months, showed that gene and
protein expression of CYP1A2 in the liver was induced by cigarette
smoke and not by exposure to THS aerosol. In addition, a reduction
in CYP1A2 gene and protein expression to levels approaching those
of cessation was observed after switching from cigarette smoke
exposure to THS aerosol exposure (Lo Sasso et al., 2016). Thus, the
reduction in enzymatic activity of CYP1A2 as observed upon
smoking cessation is an additional indicator of reduced exposure to
HPHCs when subject use THS for 5 days.
Exposure to nicotine was comparable between the THS and CC
groups at Baseline. After an initial decrease at Day 1 values
increased by Day 5 to similar levels in the THS and CC group. Thechange from CC to the THS requires adaptation and CC smokers
had therefore to adjust to a new product with a different nicotine
yield, taste and sensory characteristics compared to their own
brand of CC. The decrease in nicotine levels observed at Day 1
was likely caused by this switch and the start of the adaptation
process. This process appears to be accompanied by a change in
human pufﬁng topography, with an increase in puff count, puff
frequency and puff duration, to compensate for a decrease in
average puff volume and initial drop in total puff volume at Day 1.
Furthermore a slight initial drop in number of THS tobacco sticks
consumed on Day 1, which was lower than the number of average
CC smoked at baseline, and recovery back to levels of THS tobacco
stick use observed at baseline by Day 3 adds an explanation to
the observed nicotine proﬁle.
The results of the QSU-brief showed similar reductions in urge-
to-smoke for THS 2.2 relative to CC and were distinct to that which
was observed during SA. As expected, smoking abstinence drove an
urge-to-smoke increase from Day 1 onwards with an increase of
23% from Baseline. This increase was slightly lower in magnitude
but overall consistent with data from the literature, where an in-
crease of approximately 54% was observed in smokers 24 h post
smoking abstinence. (West and Ussher, 2010).
The mCEQ scale however showed that over the course of the
study, psychological reward and smoking satisfaction were lower
for participants who switched to THS 2.2 compared to those who
continued to smoke CC, while there were no notable differences in
aversion, craving reduction, and enjoyment of respiratory tract
sensation. The combination of the results for nicotine uptake and
subjective results are indicative of a smooth transitional adaptation
towards an acceptance of the product, although due to the short
duration of the study, participants with a long history of smoking
their own CCs may not have been able to completely adjust to THS
2.2 before the study end. Nevertheless, overall subjective effect
measures, daily product consumption numbers together with HPT
data as well as nicotine uptake indicate that THS 2.2 offered an
acceptable experience for a current CC smokers.
However, the study should be taken with the limitations
inherent to the design. The study was too short to fully assess the
reduction in exposure to NNKwith THS 2.2 use as total NNAL has an
apparent half-life of 10e18 days (Goniewicz et al., 2009). Never-
theless, the relative reduction of 56% in the levels of total NNAL, a
tobacco speciﬁc-nitrosamine for which an association with lung
cancer is demonstrated in smokers, is extremely promising as one
can expect even further decline, considering the long-half-life of
this metabolite, under prolonged use of THS. Finally, the clinic-
conﬁned setting, is a limit to the generalization of the results to a
more real world use setting, where use of other tobacco and
nicotine containing products can occur. For these reasons, longer
studies in ambulatory settings need to be conducted to evaluate
how the reductions to exposure would be sustained with less
control over product use.
Yet, this study allowed an assessment of comparative exposure
in optimal conditions, inherent to its randomized controlled design,
and the controlled ad libitum product use in a conﬁned setting
preventing from dual use.
A strength of the study was that all urinary biomarkers of
exposure were measured in 24-h urine collection using validated
methods. Compared to partial urine or spot urine, 24-h urine
collection is considered the most accurate approach to measure
excretion of the metabolites generated from exposure to HPHCs.
Furthermore the HPHCs measured in this study cover multiple
chemical classes, organ toxicity classes, half-lifes, gas and particu-
late phases, and formation temperatures, providing indication that
THS 2.2 reduces exposure to a broad spectrum of HPHCs.
C. Haziza et al. / Regulatory Toxicology and Pharmacology 81 (2016) 489e499 4995. Conclusions
The study demonstrated that switching from CC smoking to THS
2.2 use resulted in substantial reductions in exposure to 15 selected
HPHCs. The kinetics and the magnitude of decrease of biomarkers
of exposure levels observed in the THS group were approaching the
levels observed in the SA group for the majority of the biomarkers
of exposure. Nicotine uptake was similar between the THS and CC
groups at the end of the 5 day exposure period after users had
started to adapt to a new product, and with a transitional period of
changing pufﬁng behavior, were able to achieve their desired
nicotine level. The combination of the results of nicotine exposure
and subjective effect measures indicated that THS 2.2 offered
comparable satisfaction with regards to taste and sensorial expe-
rience, to that which was observed in CC smokers. No SAEs or se-
vere AEs were reported during this study, with the total number of
AEs being very low and evenly balanced across study groups.
Funding
The study was sponsored by Philip Morris Products S.A.
Conﬂict of interest statement




The authors would like to thank Dr. Hirona Miura, study Prin-
cipal Investigator, LSI Medience Corporation, Tokiwa Chemical In-
dustries Co. Ltd., and Celerion Inc. for laboratory processing of
samples.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.yrtph.2016.09.014.
Transparency document
Transparency document related to this article can be found
online at http://dx.doi.org/10.1016/j.yrtph.2016.09.014.
References
Butler, M.A., et al., 1992. Determination of CYP1A2 and NAT2 phenotypes in human
populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2,
116e127.
Cappelleri, J.C., et al., 2007. Conﬁrmatory factor analyses and reliability of the
modiﬁed cigarette evaluation questionnaire. Addict. Behav. 32, 912e923.
Cox, L.S., et al., 2001. Evaluation of the brief questionnaire of smoking urges (QSU-
brief) in laboratory and clinical settings. Nicotine Tob. Res. 3, 7e16.
Euler, D.E., et al., 1996. Effect of cigarette smoking on pentane excretion in alveolar
breath. Clin. Chem. 42, 303e308.
Faber, M.S., Fuhr, U., 2004. Time response of cytochrome P450 1A2 activity on
cessation of heavy smoking. Clin. Pharmacol. Ther. 76, 178e184.
Fagerstrom, K., et al., 2012. The Fagerstrom test for nicotine dependence as a pre-
dictor of smoking abstinence: a pooled analysis of varenicline clinical trial data.
Nicotine Tob. Res. 14, 1467e1473.FDA (Food and Drug Administration), 2001. Guidance for industry. Anal. Proced.
Methods Validation Drugs Biol. 1e25. http://www.fda.gov/downloads/Drugs/
Guidance/ucm070107.pdf.
FDA (Food and Drug Administration), 2012a. Guidance for Industry eModiﬁed Risk
Tobacco Product Applications e Draft Guidance.
FDA (Food and Drug Administration), 2012b. Guidance for Industry e Reporting
Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco
Smoke under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act e
Draft Guidance.
Forster, M., et al., 2015. An experimental method to study emissions from heated
tobacco between 100-200 degrees C. Chem. Cent. J. 9e20.
Goniewicz, M.L., et al., 2009. Elimination kinetics of the tobacco-speciﬁc biomarker
and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Cancer
Epidemiol. Biomarkers Prev. 18, 3421e3425.
Gunes, A., Dahl, M.L., 2008. Variation in CYP1A2 activity and its clinical implica-
tions: inﬂuence of environmental factors and genetic polymorphisms. Phar-
macogenomics 9, 625e637.
Haziza, C., et al., 2016. Evaluation of the tobacco heating system 2.2. Part 8: 5eDay
randomized reduced exposure clinical study in Poland. Regul. Toxicol. Phar-
macol. (under revision).
IARC (International Agency for Research on Cancer), 2012. Monographs on the
Evaluation of Carcinogenic Risks to Humans: Chemical Agents and Related
Occupations, 100F.
Imbriani, M., et al., 1999. [Signiﬁcance of urinary concentrations of S-benzyl-N-
acetylcysteine (S-BMA) in subjects exposed to toluene] Italian. G. Ital. Med. del
Lav. Ergon. 21, 329e333.
Kroon, L.A., 2007. Drug interactions with smoking. Am. J. Health Syst. Pharm. 64,
1917e1921.
Lo Sasso, G., et al., 2016. Effects of cigarette smoke, cessation and switching to a
candidate modiﬁed risk tobacco product on the liver in Apoe(-/-) mice - a
systems toxicology analysis. Inhal. Toxicol. 28, 226e240.
Lovreglio, P., et al., 2010. Validity of new biomarkers of internal dose for use in the
biological monitoring of occupational and environmental exposure to low
concentrations of benzene and toluene. Int. Arch. Occup. Environ. Health 83,
341e356.
MacLeod, S., et al., 1997. Polymorphisms of CYP1A1 and GSTM1 inﬂuence the in vivo
function of CYP1A2. Mutat. Res. 376, 135e142.
Ministry of Health and Welfare, 2013. Ministerial Ordinance on Good Clinical
Practice for Drugs. Ordinance of the Ministry of Health and Welfare No. 28 of
March 27, 1997, as last amended No. 161 of December 28, 2012. Provisional
Translation (as of March 2013). Available from: http://www.pmda.go.jp/english/
service/pdf/ministerial/20130329No_28.pdf (Accessed on 22 April 2014).
OECD (Organization for Economic Co-operation and Development), 2005. SIDS
Initial Assessment Report for SIAM 20: Isoprene. Available from: http://webnet.
oecd.org/HPV/UI/handler.axd?id¼2d19a70d-10ec-4ff9-9b9a-0978d0db8798
(Accessed on 23 June 2016).
Qadariyah, L., et al., 2011. Degradation of glycerol using hydrothermal process.
Bioresour. Technol. 102, 9267e9271.
Rodgman, A., Perfetti, T.A., 2013. The Chemical Components of Tobacco and Tobacco
Smoke. CRC Press, Taylor & Francis Inc, United States.
Royal College of Physicians, 2016. Nicotine without Smoke: Tobacco Harm Reduc-
tion. A report by the Tobacco Advisory Group of the Royal College of Physicians.
RCP, London.
Schaller, J.-P., et al., 2016. Evaluation of the Tobacco Heating System 2.2. Part 2:
chemical composition, genotoxicity, cytotoxicity, and physical properties of the
aerosol. Regul. Toxicol. Pharmacol. (under revision).
Schettgen, T., et al., 2008. Fast determination of urinary S-phenylmercapturic acid
(S-PMA) and S-benzylmercapturic acid (S-BMA) by column-switching liquid
chromatography-tandem mass spectrometry. J. Chromatogr. B Anal. Technol.
Biomed. Life Sci. 863, 283e292.
U.S. Department of Health and Human Services, et al., 1990. Toxicological Proﬁle for
Ethylene Oxide. Available from: http://www.atsdr.cdc.gov/toxproﬁles/tp137.pdf
(Accessed on 27 January 2015).
U.S. Department of Health and Human Services, 2004. The Health Consequences of
Smoking - a Report of the Surgeon General. U.S. Department of Health and
Human Services, Centers for Disease Control and Prevention, National Center
for Chronic Disease Prevention and Health Promotion, Ofﬁce on Smoking and
Health, Atlanta, GA.
Uppsala Monitoring Centre, Q1, 2013. WHO Drug Dictionary Enhanced (WHO DDE).
Available from: www.umc-products.com (Accessed on 03 November 2014).
West, R., Ussher, M., 2010. Is the ten-item questionnaire of smoking urges (QSU-
brief) more sensitive to abstinence than shorter craving measures? Psycho-
pharmacology 208, 427e432.
WHO Study Group, et al., 2008. The Scientiﬁc Basis of Tobacco Product Regulation:
Second Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1-277,
1 pp. following 277.
World Medical Association (WMA), 2008. Ethical Principles for Medical Research
Involving Human Subjects (Declaration of Helsinki).
